Global Cardiac Ablation Market

Cardiac Ablation Market Size, Share, Growth Analysis, By Product(Radiofrequency (RF), Ablators, Electrical ablators, Cryoablation devices), By Application(Atrial fibrillation & flutter, Tachycardia, and Others), By Approach(Catheter-based, and Open/Surgical), By Region - Industry Forecast 2024-2031


Report ID: SQMIG35A2459 | Region: Global | Published Date: March, 2024
Pages: 219 | Tables: 92 | Figures: 66

Cardiac Ablation Market News

  • The acquisition is anticipated to expand the company's current cardiac ablation portfolio by including its first-ever cardiac mapping and navigation platform, which would include a unique, fully integrated diagnostic, focused pulsed field, and radiofrequency ablation solution. Medtronic, a well-known global leader in healthcare technology, acquired Affera, Inc. on August 23, 2022.
  • On September 6, 2022, Johnson & Johnson MedTech, a division of Biosense Webster, Inc., introduced the OCTARAY Mapping Catheter with TRUEref Technology powered by CARTO 3 Version 7 System. For mapping cardiac arrhythmias including atrial fibrillation (AFib), the OCTARAYTM Mapping Catheter was created.
$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Cardiac Ablation Market size was valued at USD 1.29 billion in 2021 and is poised to grow from USD 1.45 billion in 2022 to USD 3.70 billion by 2030, growing at a CAGR of 14.2% in the forecast period (2023-2030).

The competitive landscape of the Cardiac Ablation market is characterized by intense rivalry among prominent players striving to innovate and capture a larger market share. Leading medical device companies such as Medtronic, Biosense Webster (a subsidiary of Johnson & Johnson), Boston Scientific Corporation, and Abbott Laboratories dominate the market with their extensive product portfolios and strong presence. These companies compete through continuous research and development, technological advancements, and strategic acquisitions to offer cutting-edge cardiac ablation solutions. 'Medtronic - USA', 'Biosense Webster (a subsidiary of Johnson & Johnson) - USA', 'Boston Scientific Corporation - USA', 'Abbott Laboratories - USA', 'AtriCure, Inc. - USA', 'MicroPort Scientific Corporation - China', 'St. Jude Medical, Inc. (now part of Abbott) - USA', 'Biotronik SE & Co. KG - Germany', 'Stereotaxis, Inc. - USA', 'Osypka Medical GmbH – Germany'

Technological breakthroughs are enhancing the effectiveness and safety of cardiac ablation procedures, attracting both patients and healthcare providers.

Minimally Invasive Procedures: There's a growing preference for minimally invasive techniques, reducing patient discomfort, hospital stays, and recovery time.

Anticipated to hold the predominant share of revenue in the cardiac ablation market throughout the forecast period, North America's prominence stems from its robust presence of leading pharmaceutical and medical equipment entities. A surge in clinical trials, favorable healthcare reimbursement policies, and substantial investments in the advancement of cardiac ablators collectively bolster the revenue trajectory in the region. The augmentation is further accentuated by a burgeoning array of product launches infused with cutting-edge technological innovations.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Cardiac Ablation Market

Report ID: SQMIG35A2459

$5,300
BUY NOW GET FREE SAMPLE